Last reviewed · How we verify
Multicenter Uveitis Steroid Treatment (MUST) Trial
The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
Details
| Lead sponsor | JHSPH Center for Clinical Trials |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 255 |
| Start date | 2005-09 |
| Completion | 2010-12 |
Conditions
- Uveitis
Interventions
- fluocinolone acetonide intraocular implant
- oral corticosteroid with immunosuppressive agents as needed
Primary outcomes
- Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis — 24 months
Best-corrected visual acuity was measured as the number of letters read from standard logarithmic visual acuity charts by study-certified examiners who were masked to treatment. Visual acuity was measured at all study visits. The primary outcome was eye-specific change in visual acuity from baseline to 2-year follow-up. Positive change values indicate improved vision while negative change values indicate vision has gotten worse. A change of 7.5 letters is considered clinically meaningful.
Countries
United States, Australia, United Kingdom